Novartis AGNOVN
▲ PositiveCapitalrelevance
Beat Q2 earnings and revenue estimates, reaffirmed 2026 outlook
Impact on stocks 2
Biotech & Genomic Medicine
Novartis AGDigital Finance & Tokenization
JPMorgan Chase & CoJPM
Mentioned
Novartis beat second-quarter expectations on both revenue and earnings while reaffirming its full-year 2026 outlook despite weaker free cash flow. The Swiss drugmaker reported adjusted earnings of $2.41 per share, beating estimates by $0.26, and revenue rose 2.6% from a year earlier to $14.41 billion, about $350 million above Wall Street expectations. Free cash flow fell 12% to $5.6 billion, making cash generation the softer part of the quarter. Management maintained its forecast for low-single-digit sales growth and a low-single-digit decline in core operating income for the full year.
Novartis AGBeat Q2 earnings and revenue estimates, reaffirmed 2026 outlook
JPMorgan Chase & Co